NCT03556007 - A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

LY3471851

LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

DRUG

Placebo

The placebo dosing solution is 0.9% sodium chloride for injection (USP).

Trial Locations (14)

11021

Investigator Site - Great Neck, Great Neck

16635

Investigator Site - Duncansville, Duncansville

28401

Investigator Site- Wilmington, Wilmington

32806

Investigator Site - Orlando, Orlando

33603

Investigator Site-Tampa, Tampa

33765

Investigator Site - Clearwater, Clearwater

36207

Investigator Site - Anniston, Anniston

38119

Investigator Site - Memphis, Memphis

38305

Investigator Site - Jackson, Jackson

44130

Investigator Site - Middleburg Heights, Middleburg Heights

75150

Investigator Site - Mesquite, Mesquite

75231

Investigator Site - Dallas, Dallas

78745

Investigator Site - Austin, Austin

92037

Investigator Site - La Jolla, La Jolla